ストックスクリーナーアプリを入手
4.63
1.70%
-0.08
前日終値:
$4.71
開ける：
$4.68
24時間の取引高:
574.23K
Relative Volume:
0.66
時価総額：
$572.50M
収益：
$58.49M
当期純損益:
$-105.04M
株価収益率:
-3.5624
EPS:
-1.2997
ネットキャッシュフロー:
$-13.78M
1週間 パフォーマンス:
-7.40%
1か月 パフォーマンス:
+5.71%
6か月 パフォーマンス:
-60.53%
1年 パフォーマンス:
-55.95%
1日の値動き範囲:
$4.55
$4.9795
1週間の範囲:
$4.46
$5.21
52週間の値動き範囲:
$4.18
$13.77
Immatics N V Stock (IMTX) Company Profile
IMTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
4.63 | 572.50M | 58.49M | -105.04M | -13.78M | -1.2997 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-07 | 開始されました | Piper Sandler | Overweight |
| 2023-11-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-31 | 開始されました | Mizuho | Buy |
| 2023-03-24 | 開始されました | Bryan Garnier | Buy |
| 2020-11-20 | 開始されました | BofA Securities | Buy |
| 2020-09-22 | 開始されました | Goldman | Buy |
| 2020-07-27 | 開始されました | SVB Leerink | Outperform |
| 2020-07-24 | 開始されました | Jefferies | Buy |
すべてを表示
Immatics N V (IMTX) 最新ニュース
Immatics Reports Strong 2024 Financial Results and Progress - TipRanks
Immatics N.V.: Trading Below Cash, But Not Without Reason (NASDAQ:IMTX) - Seeking Alpha
Immatics NV earnings beat by €0.74, revenue topped estimates - Investing.com
Immatics NV reports results for the quarter ended December 31Earnings Summary - TradingView
Immatics Announces Full Year 2024 Financial Results and Business Update - GlobeNewswire
Immatics Advances Cancer Immunotherapy with Phase 3 Trial and Strong Financials - TipRanks
Breakthrough: Immatics' Melanoma Treatment Achieves 54% Response Rate as Phase 3 Trial Advances - StockTitan
Immatics (NASDAQ:IMTX) Trading Down 5.3% – Time to Sell? - Defense World
IMMATICS N.V Earnings Preview: Recent $IMTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
(IMTX) Trading Report - Stock Traders Daily
Immatics (IMTX) Projected to Post Earnings on Thursday - Defense World
Short Interest in Immatics (NASDAQ:IMTX) Declines By 11.9% - Defense World
TCR Therapy Clinical Trial Pipeline Accelerates as 80+ Pharma Companies Rigorously Developing Drugs for the Market Entry | DelveInsight - GlobeNewswire Inc.
Y Intercept Hong Kong Ltd Buys New Position in Immatics (NASDAQ:IMTX) - Defense World
Immatics (NASDAQ:IMTX) adds US$66m to market cap in the past 7 days, though investors from a year ago are still down 61% - Simply Wall St
Immatics N.V (IMTX) Recovers -2.54% From Low: Are We There Yet? - Stocks Register
Financial Metrics Unveiled: Immatics N.V (IMTX)’s Key Ratios in the Spotlight - The Dwinnex
Immatics (NASDAQ:IMTX) Sets New 1-Year Low – What’s Next? - Defense World
(IMTX) Trading Signals - Stock Traders Daily
Immatics (NASDAQ:IMTX) Reaches New 1-Year LowHere's What Happened - MarketBeat
abrdn plc Buys 114,479 Shares of Immatics (NASDAQ:IMTX) - MarketBeat
Immatics (NASDAQ:IMTX) Trading Down 4.7% – What’s Next? - Defense World
Investors in Immatics (NASDAQ:IMTX) have unfortunately lost 53% over the last year - Yahoo Finance
Immatics N.V (IMTX): An Important Analyst Insights - Stocks Register
Financial Metrics Check: Immatics N.V (IMTX)’s Ratios for Trailing Twelve Months - The Dwinnex
Immatics (NASDAQ:IMTX) Reaches New 52-Week LowTime to Sell? - MarketBeat
Examining Immatics N.V (IMTX) more closely is necessary - US Post News
It is Poised to be a Bull Market for Immatics N.V (IMTX) - SETE News
Immatics N.V (IMTX) Becoming More Attractive for Investors - Knox Daily
Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in January - MarketBeat
Immatics (NASDAQ:IMTX) Hits New 52-Week LowShould You Sell? - MarketBeat
Immatics N.V (IMTX) Volatility Hits 4.72% – Here Is What You Should Do - Stocks Register
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Immatics (NASDAQ:IMTX) - Defense World
Brokers Offer Predictions for Immatics FY2025 Earnings - ETF Daily News
Cantor Fitzgerald Predicts Immatics FY2025 Earnings - Defense World
Cantor Fitzgerald Forecasts Immatics FY2025 Earnings - MarketBeat
Is Immatics N.V. (IMTX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Immatics (NASDAQ:IMTX) Short Interest Up 13.1% in December - MarketBeat
Immatics (NASDAQ:IMTX) Shares Sold by JPMorgan Chase & Co. - Defense World
Immatics (NASDAQ:IMTX) Shares Down 3.9%What's Next? - MarketBeat
Down -16.85% in 4 Weeks, Here's Why Immatics (IMTX) Looks Ripe for a Turnaround - Yahoo Finance
Revenues Working Against Immatics N.V.'s (NASDAQ:IMTX) Share Price - Simply Wall St
Immatics N.V.: Considering More Engineered T Cells For Cancer (NASDAQ:IMTX) - Seeking Alpha
IMTX: 3 Small-Cap Healthcare Stocks With Big Upside Potential - StockNews.com
Analyzing Immatics (NASDAQ:IMTX) & Kyverna Therapeutics (NASDAQ:KYTX) - Defense World
Immatics N V (IMTX) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):